01—Abstract
Summary
Summary of the 8-K/A filed May 12, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (WST) filed this Form 8-K/A on May 12, 2025 to supplement its original Form 8-K filed May 8, 2025.
The filing states that shareholders approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan (the "Plan"). The filing indicates that the material provisions of the amended Plan are described extensively in the company's definitive proxy statement filed on March 21, 2025. The purpose of this amendment is to attach the amended and restated Plan itself as Exhibit 10.15, which qualifies the proxy description in its entirety.
The filing also includes Exhibit 104, the Inline XBRL cover page from the company's Current Report on Form 8-K dated May 6, 2025. For investors, this filing is administrative in nature.
It contains no new financial results or operating figures. Its significance lies in documenting the governing terms of the equity and incentive compensation plan that shareholders approved.
02—Key points
Key Highlights
- Form 8-K/A filed May 12, 2025, supplementing the original Form 8-K filed May 8, 2025
- Shareholders approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan
- Plan provisions are described in the definitive proxy statement filed March 21, 2025
- Amended and restated Plan is filed as Exhibit 10.15 and qualifies the proxy description in its entirety
- Exhibit 104 provides the Inline XBRL cover page from the Form 8-K dated May 6, 2025
- No new financial results or operating figures are reported in this filing
03—Questions
Frequently Asked Questions
What did shareholders approve?
Shareholders approved an amendment and restatement of the company's 2016 Omnibus Incentive Compensation Plan, as noted in the original Form 8-K filed May 8, 2025.
Where can investors find the details of the amended Plan?
The filing states that the material provisions are described extensively in the definitive proxy statement filed March 21, 2025. The full amended and restated Plan is attached as Exhibit 10.15 to this Form 8-K/A and qualifies that description in its entirety.
Why was this Form 8-K/A filed?
The filing supplements the original Form 8-K filed May 8, 2025, to attach the amended and restated Plan as Exhibit 10.15.
Does this filing report any financial results?
No. The filing addresses Item 5.02 (compensatory arrangements) and Item 9.01 (exhibits) only, and includes no financial results or operating figures.
04—Continue